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Acute and chronic inﬂammations of mucosal surfaces are complex events in which the eﬀector mechanisms of innate and adaptive
immune systems interact with pathogenic and commensal bacteria. The role of constitutive and inducible antimicrobial peptides
in intestinal inﬂammation has been investigated thoroughly over the recent years, and their involvement in various disease states
is expanded ever more. Especially in the intestines, a critical balance between luminal bacteria and the antimicrobial peptides is
essential, and a breakdown in barrier function by impaired production of defensins is already implicated in Crohn’s disease. In this
paper, we focus on the role of antimicrobial peptides in inﬂammatory processes along the gastrointestinal tract, while considering
the resident and pathogenic ﬂora encountered at the speciﬁc sites. The role of antimicrobial peptides in the primary events of
inﬂammatory bowel diseases receives special attention.
1.Introduction
Although a host of diﬀerent bacteria colonizes the gut from
the oral cavity to the rectum, translocation of bacterial
agents through the intestinal walls remains limited to highly
pathogenic bacteria or predisposing disease states in which
the natural defense mechanisms are compromised.
In the healthy individual, the physical barrier created
by the thin layer of epithelium forms the basis of the
mucosal defense. In addition, the production of an array
of antimicrobial peptides by secretory epithelial cells limits
the invasion and adherence of pathogenic and commensal
bacteria. Salient examples of antimicrobial peptides are
the defensins and cathelicidin LL37, the two major classes
of AMPs in mammals, yet other molecules like elaﬁn or
secretory leukocyte protease inhibitor (SLPI) complement
the eﬀector mechanisms of innate and adaptive immune
systems. Equally important, in the small and large intestine,
goblet cells are responsible for the production of highly
glycosylated proteins, which form a gel-like layer over
the surface epithelium. The outer portion of this layer is
heavily colonized by bacteria, whereas the inner stratum’s
low bacterial load results from the high local levels of
antimicrobial peptides [1].
Recent years have seen a steadily rising interest in antimi-
crobial peptides, and their implication in the pathogenesis
of intestinal processes like Crohn’s disease [2] or necrotizing
enterocolitis [3] as well as their role in psoriasis and atopic
dermatitis, cystic ﬁbrosis and otitis media has garnered the
attention of an increasing group of scientists.
In this paper, we would like to focus on the role of
antimicrobial peptides in inﬂammatory processes along the
gastrointestinal tract, while considering the resident and
pathogenic ﬂora encountered at the speciﬁc sites. The role of
antimicrobial peptides in the pathogenesis of the idiopathic
inﬂammatory bowel diseases receives special attention.
2.AntimicrobialPeptidesof
theGastrointestinalmucosa
2.1. Defensins. Defensins serve as endogenous antibiotics
with microbicidal activity against Gram-negative and Gram-
positive bacteria, fungi, viruses, and protozoa [4]. One of
their fundamental characteristics is the presence of three
intramolecular disulﬁde bonds. The pattern of linkage
between the cystein residues allows the classiﬁcation into
two major groups, the α-defensins and the β-defensins (the
cyclic octadecapeptide called θ-defensin were not found2 International Journal of Inﬂammation
in humans so far). The former are linked by a 1–6, 2–
4, 3–5 pattern, the latter 1–5, 2–4, 3–6 pattern, yet their
three-dimensional structure is similar [5, 6]. The total of
six α-defensins includes human neutrophil peptides 1–4
(HNP1–4) produced by granulocytes and human defensin
5 and 6 (HD5 and HD6) produced by Paneth cells. It
should be noted that the Paneth cell defensins are stored
as propeptides and require cleavage by trypsin, which
is stored in Paneth cell granules as a zymogen as well
[7, 8].
β-defensins are mainly produced by epithelial cells [9],
and four subtypes, designated hBD-1 to hBD-4, have been
identiﬁedinthehumanmucosasofar.hBD-1isubiquitously
expressed at all surfaces of the human body including the
skin, the respiratory, urogenital and the gastrointestinal
tract [10–15]. hBD-2 and hBD-3 are inducible antimicrobial
peptides expressed by enterocytes throughout the intestinal
tract on demand.
Biochemical properties of the human defensin family
include a low molecular mass from 3 to 6kDa and a cationic
charge, which allows these molecules to bind to negatively
charged phospholipid groups on microbial surfaces. The
exact mechanism by which defensins exert their bactericidal
eﬀect has still not been identiﬁed, but it has already become
clear that they do not act with a uniform mechanism. One
model, the “Shai-Matsuzaki-Huangh” model, proposes that
after integration of defensins into the cell membrane, its
outer layer expands and strains the inner leaﬂet of this
bilayer, leading to disruption or formation of toroidal pores
[16]. On the other hand, hBD-3 has been shown to function
rather by inhibiting steps of the biosynthesis of the bacterial
cell wall [17].
Defensins were also noted for their chemotactic proper-
ties. The chemoattractant eﬀect on immature dendritic cells
and CD4+ T cells has been shown to act through chemokine
receptor CCR6 [18]. Chemoattraction of macrophages and
monocytes has been observed as well, but these cells do
not express CCR6. A recent publication now reported that
hBD-2 and hBD-3 are chemotactic for these cell lines in
a CCR2-dependent manner [19]. Other investigations have
shown that hBD-2 induces the migration of mast cells
by activating G-protein-phospholipase C-coupled receptors
and is a speciﬁc chemoattractant for human neutrophils
[20, 21].
In a broader concept, Peyrin-Biroulet and Chaimallard
position defensins at the interface between innate and adap-
tive immunity, proposing that NOD2-mediated microbial
recognition leads to secretion of defensins, which in turn
attractimmaturedendriticcells,helpintheirmaturationand
promote the subsequent activation of T cells [22].
Also, HD-5 may inﬂuence the intestinal inﬂammatory
response by binding to the cell membrane of intestinal
epithelial cells. A subsequent induction of interleukin-(IL-)
8 was observed in a concentration- and structure-dependent
fashion [23, 24].
2.2. Cathelicidins. The second major group of AMPs in
mammals are the cathelicidins. While a signal peptide called
“cathelin prosequence” can be found at their N-terminus,
the C-terminal part is formed by a more variable cationic
region that has antimicrobial activity once cleaved from
the holoprotein. The only cathelicidin identiﬁed in humans
was termed LL-37/h-CAP18. Its constitutive expression is
found in various immune cells, in salivary glands, and in
epithelia of respiratory, digestive and reproductive tracts
while keratinocytes and intestinal cells can be induced to
enhance expression. LL-37’s antimicrobial properties are
supplemented by its chemotactic eﬀect on blood cells,
activation of histamin release from mast cells, or induction
of angiogenesis [25].
2.3. Other Antimicrobial Peptides. Antimicrobial activity has
been noted in a multitude of other small molecules. For
example, the chemokines CCL14 and CCL15 are con-
stitutively expressed at high levels in human intestinal
epithelium and display potent antibacterial eﬀects [24].
CLL20/macrophage-inﬂammatory-protein-3α and an addi-
tional 17 chemokines function as antimicrobials as well
[26].Elaﬁnandsecretoryleukocyteproteaseinhibitor(SLPI)
also exhibit broad spectrum antimicrobial activity against
Gram-positive and Gram-negative bacteria, selected fungi
and viruses [5], though in their principal role, these antipro-
teases serve to maintain tissue integrity by antagonising
aggressive serine proteases like human neutrophil elastase
(HNE) [27]. Yet another epithelial antimicrobial peptide is
bactericidal/permeability-increasing protein (BPI), which is
involved in lipid-mediated killing and the attenuation of
proinﬂammatory signalling by bacteria. Its sphere of action
covers mostly Gram-negative bacteria [28, 29]. For a quick
overview, Table 1 lists the abovementioned antimicrobials
along with their properties.
3.AntimicrobialsinGastrointestinalDiseases
3.1. Esophagus. Microbial infections of the esophagus repre-
sent a rather uncommon event in healthy individuals. Nev-
ertheless, the immunocompromised host quite frequently
suﬀers from infections with C. albicans, CMV or HSV, while
bacterial infections remain rare.
Fittingly, despite a high expression of numerous antimi-
crobial peptides, assays with oesophageal tissue showed a
weakened potency to kill C. albicans [30], a fact which
could help explain the susceptibility of esophageal tissues
to infections with this yeast. Kiehne et al. [31]o b s e r v e d
that Candida colonization induced a high expression of a
subset of antimicrobial peptides, especially hBD-2 (shown
in Figure 1) and hBD-3. In a subsequent mechanistic
study the group showed that polymorphonuclear leukocytes
(PMNs) reinforce the defensin expression in the epithelium.
The authors speculate that individuals suﬀering from neu-
tropenia lack this stimulus for the expression of epithe-
lial antimicrobial peptides and thus, a pathophysiologic
explanation for the high incidence of Candida esophagitis
and Candida-related deaths in neutropenic patients can
be proposed [32]. Furthermore, even in esophageal reﬂux
disease, an induction of β-defensin expression (hBD-2
and hBD-3) could be found, although to a minor degree
[31].International Journal of Inﬂammation 3
Table 1: Antimicrobials in the gastrointestinal tract.
Antimicrobial
peptide
Chromosomal
location
Molecular
mass (kDa) Secretory stimuli
Distribution in
gastrointestinal
tract
Biological function
Changes in
inﬂammatory bowel
disease
hBD-1 8p23.1 3.5–4.5
Constitutive in
epithelial cells,
IFN-γ and LPS in
monocytes
Ubiquitous in
epithelial cells of
small and large
intestine,
monocytes,
monocyte-derived
dendritic cells
Antimicrobial,
chemotactic
Reduction in colonic
IBD
hBD-2, 3, 4 8p23.1 3.5–4.5
LPS, ﬂagellin
mediated by
NF-κB and AP-1
Epithelial cells,
monocytes
- Antimicrobial,
chemoattractant for
macrophages and
monocytes,
-h B D - 2 :m a s tc e l l s
and neutrophils
- Attenuated induction
observed in colonic CD
- Reduced copy
numbers for hBD-2 in
colonic CD
HD-5 and HD-6 8p23.1 3.5–4.5 NOD2 activation
(MDP, LPS) TLR
Granules of ileal
Paneth cells (also
metaplastic Paneth
cells in other areas
of intestinal tract)
Antimicrobial,
induction of IL-8
- Reduction in ileal CD,
more pronounced in
patients with NOD2
mutation
-H D - 5a n dH D - 6
expression due to
metaplastic Paneth cells
in UC and CD colon
Cathelicidin
(“LL-37”) 3p21.3 18 Butyrate, vitamin
D, bile acids, MDP
Epithelial cells,
leukocytes
Antimicrobial,
chemotactic
- Attenuated induction
in colonic CD
- Ileal CD and UC
show regular induction
Elaﬁn 20q13.12 9.8 IL-1, TNF-α Epithelial cells,
leukocytes
Antiprotease with
antimicrobial and
chemotactic
properties
Attenuated induction
in colonic CD
Secretory
phospholipase A2 16p13.1–p12 14 LPS
Epithelial and
inﬂammatory cells,
Paneth cell
granules
- Acute phase protein
involved in
eicosanoide
metabolism
- Small intestinal
mucosal defense
?
Lysozyme 12q15 16.5 ?
Gastric, pyloric
and duodenal
glands, small
intestine,
macrophages and
monocytes, not in
colonic tissue
Antimicrobial against
Gram-positive
bacteria, chemotactic
- Small intestine: no
changes observed
- Increased colonic
expression due to
metaplastic Paneth cells
BPI (bactericidal/
permeability-
increasing protein)
20q11.23 50 LPS Epithelial cells,
neutrophils
Antimicrobial, binds
LPS-compounds
No changes observed,
regular induction in
IBD
3.2. Stomach. The high prevalence and morbidity resulting
from colonization by the Gram-negative bacterium Heli-
cobacter pylori has captured much interest in the role of
antimicrobial peptides in the stomach. Though the mucosa
exhibits a strong inﬂammatory response against H. pylori
bacteria, clearance of the pathogen is unsuccessful in many
cases.
Helicobacter infection is known to lead to a signiﬁcant
induction of hBD-2 (see Figure 1), while the defensin gene
expression caused by non-Helicobacter gastritis is much
less pronounced [33], a ﬁnding which was conﬁrmed in
a pediatric cohort [34]. In a recent study, it could be
demonstrated that H. pylori induces gastric epithelial cells
to upregulate the endogenous production of hBD-2 [35],4 International Journal of Inﬂammation
Stomach
Firmicutes (e.g. enterococcus faecalis (4), left) and bacteroids
(e.g. bacteroides (6),right) those species comprise the majority
of the phyla that make up the human colonic ﬂora. A shift
towards less bacteroidetes and more ﬁrmicutes (Bacilli) has
been observed in inﬂammatory bowel disease
Paneth cell at the crypt base (IHC)
secrete defensins that regulate the
composition of the luminal ﬂora
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Small intestine
Liver
Rectum
Colon
Anus
50µm
Yeast-like cells and pseudohyphae (3)
of C. albicans induce hBD-2 and hBD-3
in the esophagus
Nissle 1917 (5) and other probiotics induce hBD-2.
Immunohistochemistry for hBD-2 in ulcerative colitis is shown
to the right
E. coli
(1)downregulates Paneth
cell defensin production
(viatype 3-scretion system)
Salmonella typhimurium
in gastric mucosa (2) induces hBD-2 (IHC shown
above to the right) and cathelicidin LL37, and is also associated
with gastric Paneth cell metaplasia andHD5 expression
H.pylori
Esophagus
Figure 1
furthermore the authors showed that this is mediated by the
cytosolic pattern recognition receptor NOD1 (nucleotide-
binding oligomerization domain 1).
Also, an analysis of single nucleotide polymorphisms
in the DEFB1 gene correlated patients with chronic active
H. pylori-induced gastritis with the SNP G-52A, suggesting
an involvement of the constitutive expressed hBD-1 in
susceptibility to this form of gastritis [36]. In the setting
of chronic H. pylori induced gastritis, intestinal metapla-
sia (replacement of the normal mucosa by a columnar
epithelium with characteristics of intestinal epithelia, e.g.,
goblet cells, Paneth cells), is a frequent event. A high
HD-5 expression has been observed by Shen et al. [37],
suggesting that in intestinal metaplasia, where α-defensin
producing Paneth cells are present, this metaplastic change
may strengthen the antibacterial response via production of
HD-5. Aside from the defensins, H. pylori is reported to
induce Cathelicidin LL-37 in gastric epithelial cells [38].
3.3. Inﬂammation of the Biliary Tree. 10%–20% of adult
populations in developed countries suﬀer from cholelithiasis
(gallstones). Though more than 80% of patients remain
asymptomatic, infections of the gallbladder or the biliary
treearecommondiseases,whichrequireantibiotictreatment
in many cases. The normal sterility of bile is maintained
by the bactericidal eﬀect of bile salts and immunoglobu-
lin A, and a notable expression of hBD-1 and hBD-2 is
documented in biliary tract epithelium and in the liver
[39]. Similarly to other anatomic sites, hBD-1 expression
is constitutive, while in the large intrahepatic bile ducts,
hBD-2 was induced by biliary obstruction or hepatolithiasis,
where these peptides contribute to the local antimicrobial
defense.
Interestingly, in the epithelium of four of ﬁve patients
with primary sclerosing cholangitis and in all controls
with normal histology [39], hBD-2 expression remained
low. Furthermore, in all bile samples which were analysed,
hBD-1 could be found constitutively, while hBD-2 was
conﬁned to those with hepatolithiasis [39]. Patients with
primary sclerosing cholangitis, especially following endo-
scopic manipulation, suﬀer from frequent bouts of infection.
Although further studies are needed, the observed lack of
induction of hBD-2 and possibly other antibacterial peptides
could be implicated in the disease mechanism.International Journal of Inﬂammation 5
D’Aldebert et al. found an intense immunostaining for
cathelicidin in human liver biliary epithelium, and showed
that bile salts (chenodeoxycholic acid and ursodeoxycholic
acid), which also possess intrinsic bactericidal properties,
induce cathelicidin expression through diﬀerent nuclear
receptors. According to their results, either farnesoid X
receptor or vitamin D receptor is involved and upon
activation, promote cathelicidin expression in the biliary
tract [40].
3.4. Intestine. The microbial colonization of the lumen
increases along the intestine, though the number of bacteria
is still very low from the duodenum to the proximal ileum.
The distal ileum contains up to 108 primarily anaerobic
bacteria per gram of luminal contents [41], whereas up
to 1011–1012 bacteria per gram colonize the colon. The
bacterial microﬂora is crucial for the maintenance of human
health and the development of the mucosal immune system.
Moreover, its contribution to the pathogenesis of the chronic
idiopathic inﬂammatory bowel diseases is widely acknowl-
edged. In these entities, a shift in microbial composition
t o w a r d sl e s sB a c t e r o i d e t e sa n dm o r eF i r m i c u t e s( B a c i l l i )h a s
already been observed (see Figure 1).
3.4.1. Small Intestinal Inﬂammation. On the one hand, the
scarcity of bacteria in the ileum can be attributed to the
hostile environment created by acid, bile, and pancreatic
secretions as well as to the phasic propulsive motility of
this part of the gut [42]. On the other hand, adaptive and
innate branches of the immune system contribute as well
to maintain a low microbial density. Paneth cells, which
are a characteristic epithelial lineage of the small intestine
and localize to the bottom of the intestinal crypts, secrete
α-defensins in response to bacterial antigens including
lipopolysaccharide and muramyl dipeptide [43]. A consti-
tutive expression of exceptionally high levels of α-defensins
HD-5 and HD-6 could be demonstrated in human small
intestines [44]. Interestingly, expression of HD-5 exceeds
expression levels of other AMPs produced by the Paneth cell
(lysozyme and sPLa2) by a factor up to 100 [45].
Instudieswithknockoutanimals,intestinalextractsfrom
micedeﬁcientforthecryptdin-processingenzymematrilysin
and thus lacking functional mature mouse α-defensins
(the mouse homologs to defensins are called cryptdins),
show decreased antimicrobial activity [46], and the authors
furthermore observed that these mice are more susceptible
to orally administered bacterial pathogens as well as to DSS-
induced colitis. Other ﬁndings from a transgenic animal
study revealed that human α-defensin HD-5 transgenic
mice are resistant to infection from orally administered S.
typhimurium [47]. Interesting in this context is the fact that
S. typhimurium can downregulate HD-5 expression via a
type-3 secretion system (see Figure 1).
In addition, the Paneth cell defensins can shape the com-
position of microbial species present in the small intestinal
lumen,whilethetotalnumberofbacteriaremainsunaﬀected
[45, 48]. In a mouse model with transgenic expression of
DEFA5, Salzman et al. demonstrated that the colonization
with segmented ﬁlamentous bacteria (termed SFB, from
the genus Clostridia) was dramatically decreased when the
mice produced the human α-defensins HD-5. Interestingly
in this context is the fact that mice colonized with SFB were
shown to be more resistant to infection with Citrobacter
rodentium, a close relative to the well-known Escherichia
coli. Paneth cells also exert control over intestinal barrier
penetration by commensals and pathogenic bacteria [49],
apparently mediated by TLR (Toll-like receptor) recognition
and a subsequent induction of antimicrobial peptides. The
signalling was shown to be dependent on the expression
of the MyD88 adaptor protein inside the Paneth cell. The
release of Paneth cell secretions into the intestinal lumen
thus follows stimulation of pattern recognition receptors
(PRR, e.g., Toll-like receptors, NOD-like receptors, RIG-
I-like receptors) with pathogen-associated molecular pat-
terns, termed PAMPs, which are provided by resident and
pathogenic bacteria. Corroborating the concept of a host
driven composition of the microbial ﬂora, Petnicki-Ocweija
et al. showed that in the mouse model, the bactericidal
activity of crypt secretions of the terminal ileum was
severely compromised by NOD2 deletion, and that NOD2
expression depends on the presence of commensal bacteria
[50].
The human NOD2 protein (nucleotide-binding oli-
gomerization domain/caspase recruitment domain (NOD/
CARD) is a cytoplasmic receptor for bacterial molecules
which is predominately expressed in Paneth cells [51].
NOD2 received great attention after it was identiﬁed as
a susceptibility gene for Crohn’s disease in 2001 [52, 53].
Structuralchangesintheleucine-richrepeatregionofNOD2
result from two single nucleotide polymorphisms (SNPs)
andaninsertionmutationthatleadstoaframeshiftmutation
at Leu1007 (L1007fsinsC). The authors found that homozy-
gosity or compound heterozygosity increases the relative risk
for Crohn’s disease by as much as 40-fold compared with
individuals without mutation. Approximately one third of
patients aﬀected by ileal Crohn’s disease show mutations in
the NOD2 status [22]. Of note, the three common allelic
variants of the NOD2 gene were correlated with an increased
susceptibility only in Caucasians and studies have shown
remarkable diﬀerencesin the genetic variability ofthe NOD2
gene in diﬀerent ethnical populations. The three common
variations could not be found in Asian populations [54, 55]
and in African Americans mutation frequency as well as
the attributable risk were much lower [56]. These ﬁndings
could partially explain variations in the frequency of Crohn’s
disease in diﬀerent world populations.
A link among Crohn’s disease, NOD2, and α-defensins is
stronglysuggestedbyobservationsmadeinNOD2-knockout
micewhichexhibitadecreaseinPanethcelldefensins(crypt-
dins) alongside an impaired mucosal immune response to
orally delivered but not intraperitoneally administrated L.
monocytogenes [57]. Also, a decreased α-defensin mRNA
expression in biopsy specimens of ileal Crohn’s patients,
which was even more pronounced in patients carrying
NOD2 mutations [58, 59], was observed. The decrease
in α-defensins was independent of inﬂammation in the
specimens and not observed in ulcerative colitis or pouchitis,
an inﬂammatory control of non-Crohn’s ileitis. Of note,6 International Journal of Inﬂammation
patients with colonic Crohn’s showed unchanged levels of α-
defensins in biopsies from their ilea [60], Wehkamp 2005).
In contrast to these results, Simms et al. dispute the
notion that reduced α-defensin mRNA expression is a
primary eﬀect. The authors propose that this ﬁnding is
due to epithelial loss, as they did not observe reduced α-
defensin levels in noninﬂamed ileal mucosa in CD patients
[61]. Furthermore, the association between NOD2 mutation
(L1007fsinsC) and particularly low α-defensin levels could
not be reproduced in their cohort.
Yet, in an assessment of luminal HD-5 levels in
ileostomyﬂuids,signiﬁcantlylowerdefensinlevelsinCrohn’s
patients than in controls were observed, and especially in
those with homozygous/compound heterozygous NOD2-
mutations [62]. Elphick et al. reported furthermore that in
Crohn’s disease, the processing of pro-HD-5 to mature HD-
5 by trypsin is impaired. HD-5 in the ileostomy ﬂuid of
Crohn’s patients is predominantly present in complexes with
trypsin or chymotrypsin, suggesting an additional way by
which epithelial defense might be compromised in CD.
Other mechanisms leading to diminished Paneth cell α-
defensin function in patients with ileal CD are even more
complex. The diﬀerentiation of crypt stem cells into mature
secretory cells is governed by the so-called Wnt pathway.
Disruption of this signaling cascadeleads to impaired Paneth
cell diﬀerentiation, an event which manifests as a disordered
localization of these cells within the crypts [63]. One of
the Wnt signaling transcription factors, TCF-4, shows a
reduced expression in patients with ileal CD, independent
of the extent of inﬂammation in the biopsies [64]. Further
investigations revealed that in the ileal subset of Crohn’s
disease, a SNP in the TCF-4 promotor region (res3814570)
was signiﬁcantly more frequent than in colonic Crohn’s or in
ulcerative colitis [65].
A genomewide association study from 2007 identiﬁed
ATG16L1 as susceptibility locus for ileal Crohn’s disease
[66]. ATG16L1 protein is involved in autophagy, a process
which is essentially responsible for the degradation of
intracellular structures, but also mediates degradation of
phagocytosed or invasive bacteria. Moreover, Cadwell et al.
provided evidence that in ATG16L1 knockout mice, granule
exocytosis is abnormal [67, 68], and recently it has been
shown that recruitment of ATG16L1 to the site of bacterial
entry in the plasma membrane is dependent on activation
of NOD2 by bacteria ([69]). As the Paneth cell’s foremost
activity is the secretion of huge amounts of defensins, an
attractive interrelation can be proposed for the decreased
defensin functionality in Crohn’s disease and the mutation
in ATG16L1.
Genomewide screening could also identify X-box bind-
ing protein 1 (XBP1) as a risk factor for Crohn’s disease
and ulcerative colitis [70]. XBP1 deletion in mouse intestinal
epithelial cells leads to an increased susceptibility to DSS-
inducedcolitisandevenspontaneousenteritisoccurred[70].
Furthermore, an association study from Australia impli-
cates KCNN4, a calcium-mediated potassium channel, in
ilealCrohn’sdisease.Thischannelisinvolvedinthesecretory
mechanisms in Paneth cells, and mRNA levels are reduced
with NOD2 mutations [71].
Aside from these numerous associations between Paneth
cells and defensins in ileal inﬂammation of CD, the involve-
ment of antimicrobial peptides in active celiac disease, an
inﬂammatory disorder of the small intestine as well, has
been investigated. Vordenb¨ aumen et al. assessed a panel of
β-Defensins (hBD-1 to 4) and α-defensins (HD5-6) in duo-
denal biopsies of pediatric celiac disease patients and found a
decreasedhBD-1andhBD-4expression,whiletheremainder
of the antimicrobial peptides did not show diﬀerences to
healthy controls [34]. Although this observation conﬁrmed
previous investigations, the pathophysiologic signiﬁcance of
this expression pattern has yet to be determined.
3.4.2. Colon. The composition of the extensive colonic
microﬂora has been characterized more thoroughly by
sequencing of 16S ribosomal DNA of fecal contents. Among
the approximately 400 diﬀerent species harboured by the
human colon, two phyla clearly dominate: anaerobic Gram-
positive ﬁrmicutes (Clostridium, Bacillus, Lactobacillus)
and anaerobic Gram-negative bacteroidetes (Bacteroides,
Flavobacteria) [72]. A high interindividual diversity has been
noted, though at any time, each individual carries a stable
“ﬁngerprint” pattern [73]. Considering that an epithelium
of only a single cell layer separates the bowel from the
microbe-laden lumen, this barrier is remarkably eﬀective.
In addition to secreted immunoglobulins provided by the
adaptive immune system, the innate branch oﬀers a wide
variety of antimicrobial peptides.
The ﬁrst defensin identiﬁed in the human large bowel
wastheβ-defensinhBD-1,andinthenoninﬂamedcolon,itis
the major β-defensin. A recent publication reported that the
peroxisomeproliferator-activatedreceptor(PPAR)gammais
playing a major role in the constitutive expression of hBD-
1[ 74] and conﬁrmed an earlier ﬁnding of a reduction of
hBD-1 expression in inﬂamed mucosa of IBD patients [75].
Strongly supporting an important role of hBD-1 in colonic
IBD, Kocsis et al. have reported a genetic association of hBD-
1 SNPs with colonic Crohn’s disease in a Hungarian cohort
[76]. These ﬁndings challenge the perspective that reduced
defensin expression is merely the result of epithelial loss in
inﬂammatory states [77].
In the healthy colon, hBD-2 and hBD-3 are absent and
only induced during inﬂammation or infection. Stimuli for
hBD-2 induction comprise both bacteria and cytokines,
like Campylobacter jejuni [78] or the bacterial component
ﬂagellin from the E. coli strain Nissle 1917 (shown in
Figure 1), which is used as probiotic in the maintenance
treatment of ulcerative colitis [79]. On the cytokine level, the
induction is mediated by proinﬂammatory cytokines such
as IL-1β (through NF-κB-dependent and AP-1-dependent
pathways) and TNF-α [80]o rI L - 1 7[ 81].
Diﬀerent defensin mRNA expression in the diﬀerent
forms of inﬂammatory bowel diseases has been noted,
as in patients with ulcerative colitis, hBD-2 and hBD-3
are strongly induced in the event of inﬂammation. In
comparison, the induction is attenuated in Crohn’s disease
[14, 82, 83] and the colonic mucosa of Crohn’s disease
patients is compromised in the killing capacity towards
diﬀerent commensal bacteria [84]. The mechanism behindInternational Journal of Inﬂammation 7
the reduced hBD-2 expression in inﬂamed colonic Crohn’s
has not been elucidated up to now. In a European and US
cohort,genecopynumbersforhBD-2[85]werereduced,but
results from a New Zealand Cohort were inconsistent with
this ﬁnding [86].
As NOD2 mutations have been generally associated with
Crohn’s disease, researchers also investigated the eﬀects of
NOD2mutationsontheexpressionofβ-defensins.Vossetal.
demonstrated that the expression of hBD-2 is mediated by
NOD2 activation [87], but a subanalysis stratiﬁed for NOD2
mutation status could not identify diﬀerences in colonic
hBD-2 expression (Wehkamp, unpublished observation).
Further investigations revealed that 1,25-dihydroxyvitamin
D3 and MDP induce expression of hBD-2 and cathelicidin
through stimulation of NOD2 expression [88].
Many lines of evidence thus point to a major role of
β-defensins in inﬂammatory processes of the colon. New
data for the α-defensins from a mouse model show that
the Paneth cell cryptdins synthesized in the ileum retain
their structure and functionality till the colonic lumen [89],
suggestingarolefor α-defensinsinthelargebowel aswell.As
has been mentioned above, Paneth cell metaplasia is noted
on diﬀerent sites of inﬂammation along the gastrointestinal
tract, including the colon [90]. This metaplastic response
could therefore represent a mechanism that provides addi-
tional protection by α-defensins at these sites. Furthermore,
an interesting observation by Langhorst et al. showed a
signiﬁcant elevation of hBD-2 peptide in fecal samples
from patients with irritable bowel syndrome, a condition
whichdemonstratesnomacroscopicvisibleinﬂammationon
colonoscopy [91].
The antimicrobial peptide elaﬁn shares a similar expres-
sionpatternwiththeinducibleβ-defensin,LL37andsecreted
leukocyte protease inhibitor. Its additional function as
an antiprotease balances the proteolytic eﬀects of HNE
(humanneutrophilicelastase)frompolymorphonuclearcells
in healthy tissues. Moreover, it has been found to be
reduced in colonic Crohn’s disease, which could point to an
involvement of protease-antiprotease disbalance explaining
in part the penetrating, transmural type of inﬂammation
[92].
Cathelicidin (LL37) shows induction in inﬂamed tissues
of ulcerative colitis, while in active Crohn’s disease the
induction seems to be attenuated [93]. In mutant mice,
Cathelicidin restricts colonization with epithelial adherent
bacterial pathogens like Citrobacter rodentium [94], conﬁrm-
ingitsvitalroleinthearmamentariumoftheinnateimmune
system.
The large intestine harbors a complex ecosystem, where
classical immune cells and colonic epithelial cells interact
in concert with the dense resident microﬂora [95]. After
recognizing the importance of the microbiota in chronic
intestinal inﬂammation too, the characterization of the
enteric luminal ﬂora in inﬂammatory bowel disease revealed
diﬀerences in the composition compared to healthy controls.
Swidsinski et al. [96] among others demonstrated that
mucosa-associatedbacteriaaredramaticallyincreasedinIBD
mucosa. Anaerobic Bacteroides species and aerobic Enter-
obacteriaceae (E. coli) were most prevalent and furthermore
early disease recurrence seemed to be accompanied by
increased numbers of E. coli, Bacteroides, and Fusobacterium.
4. Therapeutic Consequences
Taken together, defensins seem to be attractive targets
for pharmacologic intervention in a range of diseases.
In the case of inﬂammatory bowel disease, Kubler et al.
examined the eﬀect of the currently available treatments
(immunomodulators like azathioprine, corticosteroids or
aminosalicylates) on the expression of main antimicrobial
defensins, but no signiﬁcant changes could be observed
[97]. Treatment with the anti-TNF antibody inﬂiximab was
reportedly associated with normalization of defensin mRNA
expression [77], but this was interpreted as a general eﬀect
stemming from epithelial regeneration. New insights in
the genetics of antimicrobial peptides and their respective
pathways of induction, regulation, and secretion could lead
to therapeutic strategies which aim to strengthen barrier
defense on epithelial surfaces. As detailed above, in the
Paneth cell, numerous mechanisms leading to defective α-
defensin function have been identiﬁed and can oﬀer sweet
spots for directed therapies in the future. Probiotics are
eﬀective as a maintenance treatment in colonic IBD, which
hasalreadybeenshowninaplacebocontrolled,double-blind
study with the bacterium E. coli Nissle 1917 [98]. A recent
meta-analysis conﬁrmed the beneﬁcial eﬀect of probiotic
treatment in the maintenance of ulcerative colitis [99]. A
possible mechanism is the induction of hBD-2, which has
been demonstrated for E. coli Nissle, as well as for other
therapeutic probiotic E. coli strains and Lactobacilli [100–
102].
Moreover, induction of antimicrobial peptides by agents
like worm eggs, vitamin D, speciﬁc bacteria, food, artiﬁcial
components, or possibly prebiotics may also be helpful.
A larger, dose ﬁnding phase II clinical trial with live ova
from Trichuris suis (porcine whipworm) is about to be
initiated in autumn 2010, as previous small studies have
been shown to improve the clinical outcome in ulcerative
colitis (a double-blind clinical study) and in Crohn’s disease
(an open-label study) [103, 104]. Iatrogenic infection with
these parasitic worms (Helminths), which are not able to
survive in the human intestine for longer than 12 days,
is thought to modulate the immune response. Evidence
for these ﬁndings come from the observation that children
with helmintic infections have reduced atopy [105], and
peripheral blood mononuclear cells increase the production
of anti-inﬂammatory mediators IL-10 and TGF-β [106].
Whether the therapeutic eﬀect is mediated by a shift in
adaptive immune function, or whether stimulation of the
production of antimicrobials is signiﬁcantly involved, is
an intriguing question. We hope to address this within
the context of the aforementioned study. However, recent
animal studies have provided evidence that infection with
Hymenolepis diminuta, also known as rat tapeworm, can
cause a signiﬁcant disease exacerbation as well [107]. Thus,
the therapeutic use of helminths in IBD has to be considered
carefully and its risk potential has to be assessed meticu-
lously.8 International Journal of Inﬂammation
In any case new treatment alternatives for inﬂammatory
bowel diseases are eagerly anticipated by patients and
physiciansalike,andmostprobably,advanceswillcomefrom
the ﬁeld of innate immunity.
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